02699nas a2200349 4500008004100000022001400041245011800055210006900173260000800242490000700250520161600257653000901873653001201882653001801894653002601912653001101938653001801949653001901967653001801986653002202004653002402026653001502050653001202065653002702077100002502104700002002129700002002149700002002169700001902189700001902208856012202227 2017 eng d a0928-493100aMultifunctional inulin tethered silver-graphene quantum dots nanotheranostic module for pancreatic cancer therapy0 aMultifunctional inulin tethered silvergraphene quantum dots nano cSEP0 v783 a

Cancer nanotechnology is an emerging area of cancer diagnosis and therapy. Although considerable progress has been made for targeted drug delivery systems to deliver anticancer agents to particular site of interest, new nanomaterials are frequently being developed and explored for better drug delivery efficiency. In the present work, we have explored a novel nanoformulation based on silver-graphene quantum dots (Ag-GQDs) nanocomposite for its successful implementation for pancreatic cancer specific drug delivery in wistar rats. Carboxymethyl inulin (CMI); a modified variant of natural polysaccharide inulin is tethered with the nanocomposite via carbodiimide coupling to enhance the biocompatibility of nanoformulation. Experiments are performed to investigate the cytotoxicity reduction of silver nanoparticles after inulin tethering as well as anticancer efficacy of the system using 5-Fluorouracil (5-FU) as model drug. SEM, TEM, FT-IR, UV-vis, photoluminescence and anti proliferative assays (MTT) are performed for characterisation of the nanocomposite. Hyaluronic acid (HA) is conjugated as targeting moiety for CD-44 (cancer stem cell marker) to fabricate a complete targeted drug delivery vehicle specific for pancreatic cancer. In the present work two prime objectives were achieved; mitigation the toxicity of silver nanoparticles by inulin coating and it's in vivo application for pancreatic cancer. (C) 2017 Elsevier B.V. All rights reserved.

10aacid10aDextran10aDrug-delivery10agraphene quantum dots10aInulin10aNanocomposite10aNanocomposites10aNanoparticles10aPancreatic Cancer10aSilver nanoparticle10aStrategies10aSystems10aTargeted Drug Delivery1 aJoshi, Preeti, Nigam1 aAgawane, Sachin1 aAgawane, Sachin1 aAgawane, Sachin1 aSarkar, Dhiman1 aSarkar, Dhiman uhttp://library.ncl.res.in/content/multifunctional-inulin-tethered-silver-graphene-quantum-dots-nanotheranostic-module02321nas a2200241 4500008004100000022001400041245014000055210006900195260000800264300001100272490000700283520143600290653002701726653002901753653002001782653002301802653002701825653002701852100001801879700002801897700002701925856012701952 2020 eng d a1773-224700aUnderstanding fundamentals of hepatocellular carcinoma to design next-generation chitosan nano-formulations: Beyond chemotherapy stride0 aUnderstanding fundamentals of hepatocellular carcinoma to design cAUG a1017230 v583 a

Hepatocellular carcinoma (HCC) is the deadliest form of liver cancer. Clinically, the main strategies currently being used for the treatment of HCC are surgery, radiotherapy and chemotherapy. Conventional chemotherapy has major drawbacks such as poor bioavailability, high-dose requirements, adverse side effects, low therapeutic indices, and non-specific drug targeting. Therefore, targeted drug delivery systems are fast becoming new tools for the selective killing of cancer cells. Chitosan (CS) is a biodegradable, biocompatible, cationic and natural biopolymer that also exhibits anti-cancer property which is now being explored as a promising candidate for targeted drug delivery. This review outlines an overview of the causative agents, microenvironment, pathophysiology, surface-biomarkers and physiological barriers of HCC. Then, the cellular internalization pathways of nanomedicine and the important physicochemical properties of delivery agents are discussed. The benefits of targeted therapy over conventional therapy with regard to HCC are also discussed. The main objective of this review was to summarize the current knowledge in the field of chitosan-based drug delivery for the management of HCC along with its limitations in a comprehensive and systematic way. This review attempts to provide a holistic roadmap for designing the next-generation chitosan-based drug delivery systems for HCC management.

10achitosan nanoparticles10aHepatocellular carcinoma10aPathophysiology10aSurface biomarkers10aTargeted Drug Delivery10aTumor microenvironment1 aJaiswal, Neha1 aChaudhari, Ravindra, D.1 aChaudhari, Bhushan, P. uhttp://library.ncl.res.in/content/understanding-fundamentals-hepatocellular-carcinoma-design-next-generation-chitosan-nano02535nas a2200229 4500008004100000022001400041245013200055210006900187260000800256300001100264490000800275520170400283653001801987653002802005653002902033653002702062100002102089700001802110700002302128700002702151856012702178 2023 eng d a0009-308400aChallenges and emerging strategies for next generation liposomal based drug delivery: an account of the breast cancer conundrum0 aChallenges and emerging strategies for next generation liposomal cJAN a1052580 v2503 a

The global cancer burden is witnessing an upsurge with breast cancer surpassing other cancers worldwide. Furthermore, an escalation in the breast cancer caseload is also expected in the coming years. The conventional therapeutic regimens practiced routinely are associated with many drawbacks to which nanotechnological in-terventions offer a great advantage. But how eminent could liposomes and their advantages be in superseding these existing therapeutic modalities? A solution is reflected in this review that draws attention to a decade-long journey embarked upon by researchers in this wake. This text is a comprehensive discussion of liposomes, the front runners of the drug delivery systems, and their active and passive targeting approaches for breast cancer management. Active targeting has been studied over the decade by many receptors overexpressed on the breast cancer cells and passive targeting with many drug combinations. The results converge on the fact that the actively targeted formulations exhibit a superior efficacy over their non-targeted counterparts and the all lipo-somal formulations are efficacious over the free drugs. This undoubtedly underlines the dominion of liposomal formulations over conventional chemotherapy. These investigations have led to the development of different liposomal formulations with active and passive targeting capacities that could be explored in depth. Acknowl-edging and getting a deeper insight into the liposomal evolution through time also unveiled many imperfections and unchartered territories that can be explored to deliver dexterous liposomal formulations against breast cancer and more in the clinical trial pipeline.

10aBreast cancer10aLiposomal metamorphosis10aReceptor-ligand dynamics10aTargeted Drug Delivery1 aMoudgil, Aliesha1 aSalve, Rajesh1 aGajbhiye, Virendra1 aChaudhari, Bhushan, P. uhttp://library.ncl.res.in/content/challenges-and-emerging-strategies-next-generation-liposomal-based-drug-delivery-account